Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemothera
about
Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activityIdentifying novel genes and biological processes relevant to the development of cancer therapy-induced mucositis: An informative gene network analysis.Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsIntragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity.Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity.Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenaseDihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai.A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activityEvaluation of ultra-deep targeted sequencing for personalized breast cancer care.Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer.DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis.Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity.Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.Novel Deleterious Dihydropyrimidine Dehydrogenase Variants May Contribute to 5-Fluorouracil Sensitivity in an East African Population.Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients.Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity.Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update.Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase.Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes.Germline pharmacogenomics of DPYD*9A (c.85T>C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines.Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase gene
P2860
Q33576321-AB624C34-DB7E-423F-A973-2184BF1E5AEAQ33874148-8EDEDD19-0F0A-462C-85DA-43F8214F8F0DQ34008793-1FC58779-8E46-4C56-A426-C05471349B9DQ34134768-F409451E-F447-4028-AFC5-8BF9E60CEEEEQ34216563-ADB1D646-5F75-4A31-AF29-F849F72C898AQ35585759-7F2C2E46-466D-4038-8374-44E506011FCEQ36117656-5B8ADB98-8194-4A57-AD81-2EB54CE919DDQ37092485-22462931-B281-4A7A-B524-63E93AA6694EQ37290672-DC267646-2524-4B34-B4EA-8E9E3682E610Q37690220-70076850-2008-4B26-A8B6-7D9E90820E69Q38075827-C0B53A6E-092D-4DC2-A18E-47469807908BQ38127715-90F39006-9AA1-43D9-9C10-349E4189E46DQ39208906-48AEFD11-2F8E-447F-A3FA-FDCE37DA477FQ39566084-2F09E604-20DA-462E-98D0-4E8B47F76022Q40546452-B0E35670-9AE9-41F9-9EDC-36C59D428640Q42018846-7B55335D-F159-4CF2-9A05-ADA0B56139FDQ42210747-91F88BED-4FBC-42EE-8C70-DD2F83734913Q42691338-FC00B530-4C31-41DC-A5BF-28E4BD124D92Q47135784-B7A99409-E9B8-43C9-A3FB-15F050149678Q50073098-2C3E6986-BEE0-40E3-8D04-4DDF3CF1E334Q52591829-5BEA9789-5E85-4CE7-AD7C-BF3601AB162CQ55668963-0C2D7AC5-6115-4EDE-8B78-77B4F86D7CC6Q57815793-D8A09AA7-42E8-4DDF-80FD-19B4DBFC2A91
P2860
Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemothera
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Influence of dihydropyrimidine ...... oropyrimidine-based chemothera
@ast
Influence of dihydropyrimidine ...... oropyrimidine-based chemothera
@en
type
label
Influence of dihydropyrimidine ...... oropyrimidine-based chemothera
@ast
Influence of dihydropyrimidine ...... oropyrimidine-based chemothera
@en
prefLabel
Influence of dihydropyrimidine ...... oropyrimidine-based chemothera
@ast
Influence of dihydropyrimidine ...... oropyrimidine-based chemothera
@en
P2093
P356
P1433
P1476
Influence of dihydropyrimidine ...... oropyrimidine-based chemothera
@en
P2093
J Fidlerova
K Bouskova
P Kleiblova
S Kormunda
P304
P356
10.4149/NEO_2009_04_303
P577
2009-01-01T00:00:00Z